<code id='3953EE29F4'></code><style id='3953EE29F4'></style>
    • <acronym id='3953EE29F4'></acronym>
      <center id='3953EE29F4'><center id='3953EE29F4'><tfoot id='3953EE29F4'></tfoot></center><abbr id='3953EE29F4'><dir id='3953EE29F4'><tfoot id='3953EE29F4'></tfoot><noframes id='3953EE29F4'>

    • <optgroup id='3953EE29F4'><strike id='3953EE29F4'><sup id='3953EE29F4'></sup></strike><code id='3953EE29F4'></code></optgroup>
        1. <b id='3953EE29F4'><label id='3953EE29F4'><select id='3953EE29F4'><dt id='3953EE29F4'><span id='3953EE29F4'></span></dt></select></label></b><u id='3953EE29F4'></u>
          <i id='3953EE29F4'><strike id='3953EE29F4'><tt id='3953EE29F4'><pre id='3953EE29F4'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:explore    - browse:5
          Brain cancer
          Michelle Monje/Stanford University/NIH

          Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

          The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

          advertisement

          “We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time